Aldactone Related Published Studies
Well-designed clinical trials related to Aldactone (Spironolactone)
Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. [2008.04]
Hemodynamic effects of propranolol with spironolactone in patients with variceal bleeds: A randomized controlled trial. [2008.03.28]
Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. [2008.03]
The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. [2007.07.17]
Does the aldosterone: renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study. [2007.05.09]
Effect of spironolactone on blood pressure in subjects with resistant hypertension. [2007.04]
[Efficacy and safety of long-term application of spironolactone in patients with moderate and severe chronic heart failure receiving optimal therapy] [2007]
Effect of treatment of rosacea in females by Chibixiao Recipe in combination with minocycline and spironolactone. [2006.12]
Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. [2006.11]
Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. [2006.08]
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. [2006.08]
Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. [2006.05]
Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospective analysis. [2006.05]
Appropriateness of spironolactone prescribing in heart failure patients: a population-based study. [2006.04]
Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. [2006.03]
Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study. [2005.12]
Beneficial impact of spironolactone in diabetic nephropathy. [2005.12]
Comparative pilot study of repeated large volume paracentesis vs the combination on clonidine-spironolactone in the treatment of cirrhosis-associated refractory ascites. [2005.11]
Spironolactone improves diastolic function in the elderly. [2005.10]
Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. [2005.09]
Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. [2005.07]
Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients. [2005.05]
Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: a 16-week randomized trial. [2005.04]
Spironolactone improves lung diffusion in chronic heart failure. [2005.01]
Well-designed clinical trials possibly related to Aldactone (Spironolactone)
Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. [2008.09]
A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. [2008.08]
History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. [2008.08]
Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. [2008.07]
The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. [2008.05]
Triple Pharmacological Blockade of the Renin-Angiotensin-Aldosterone System in Nondiabetic CKD: An Open-Label Crossover Randomized Controlled Trial. [2008.04.17]
Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. [2008.04]
Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial. [2008.02.21]
Insulin Sensitizers for the Treatment of Hirsutism: A Systematic Review and Meta-analyses of Randomized Controlled Trials. [2008.02.05]
Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. [2008.02]
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. [2007.12]
Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. [2007.08.14]
Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. [2007.07]
Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer-Alkmaar heart failure study. [2007.07]
Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. [2007.05]
A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. [2007.04]
Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. [2007.03]
Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. [2007.01.11]
Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition. [2007.01]
Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. [2006.12]
Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system. [2006.10]
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. [2006.09]
Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective. [2006.06]
Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. [2006.06]
Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%. [2006.05]
The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites. [2006.04]
Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. [2006.03]
Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. [2005.12]
Effects of eplerenone versus losartan in patients with low-renin hypertension. [2005.09]
Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. [2005.09]
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. [2005.08.02]
Short- and long-term results of a programme for the prevention of readmissions and mortality in patients with heart failure: are effects maintained after stopping the programme? [2005.08]
Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance. [2005.08]
Magnesium supplementation and muscle function in patients with alcoholic liver disease: a randomized, placebo-controlled trial. [2005.08]
Meditation reduces sympathetic activation and improves the quality of life in elderly patients with optimally treated heart failure: a prospective randomized study. [2005.06]
Effects of a nurse-led, clinic and home-based intervention on recurrent hospital use in chronic heart failure. [2005.03.16]
Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. [2005.03.08]
RALES, EPHESUS and redox. [2005.02]
Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. [2005.01]
Other research related to Aldactone (Spironolactone)
Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression. [2008.09]
Hyperkalemia during spironolactone use in patients with decompensated heart failure. [2008.09]
Regression of left ventricular hypertrophy and aortic remodelling in NO-deficient hypertensive rats: effect of L-arginine and spironolactone. [2008.09]
Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study. [2008.08]
[No Effect of Spironolactone on Bulimia Nervosa Symptoms.] [2008.07.29]
Fracture risk in men with congestive heart failure risk reduction with spironolactone. [2008.07.08]
Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: A randomised controlled study. [2008.07]
Spironolactone alleviates late cardiac remodeling after left ventricular restoration surgery. [2008.07]
Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. [2008.07]
Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination. [2008.07]
Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. [2008.05]
Spironolactone and gastrointestinal bleeding: a population based study. [2008.05]
A comparison of the aldosterone-blocking agents eplerenone and spironolactone. [2008.04]
Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. [2008.03.18]
Effect of Spironolactone on Diastolic Function and Left Ventricular Mass in Maine Coon Cats with Familial Hypertrophic Cardiomyopathy. [2008.03.10]
Spironolactone and gastrointestinal bleeding: a population based study. [2008.03.10]
Effect of spironolactone on diastolic function and left ventricular mass in Maine Coon cats with familial hypertrophic cardiomyopathy. [2008.03]
Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. [2008.01.05]
Effect of Renin-Angiotensin-Aldosterone System Triple Blockade on Non-Diabetic Renal Disease: Addition of an Aldosterone Blocker, Spironolactone, to Combination Treatment with an Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker. [2008.01]
Effects of spironolactone in an experimental model of chronic cyclosporine nephrotoxicity. [2008.01]
[Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy.] [2008]
Bioequivalence assessment of two formulations of spironolactone in Chinese healthy male volunteers. [2008]
Additive Effects of Spironolactone and Candesartan on Cardiac Sympathetic Nerve Activity and Left Ventricular Remodeling in Patients with Congestive Heart Failure. [2007.12]
Good blood pressure control on antihypertensives, not only response to spironolactone, predicts improved outcome after adrenalectomy for aldosteronoma. [2007.12]
Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. [2007.11]
Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs. [2007.11]
Study of the use of a spironolactone and angiotensin-converting enzyme inhibitor combination: a population-based analysis. [2007.10.22]
Zinc dyshomeostasis in rats with aldosteronism. Response to spironolactone. [2007.10]
Combination therapy with telmisartan and spironolactone alleviates L-NAME exacerbated nephrosclerosis with an increase in PPAR-gamma and decrease in TGF-beta(1). [2007.09]
Solid dispersion of spironolactone with porous silica prepared by the solvent method. [2007.08]
The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats. [2007.07]
Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. [2007.07]
Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. [2007.06]
Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats. [2007.05]
Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. [2007.04]
The effect of spironolactone use on heart failure mortality: a population-based study. [2007.04]
Low-dose spironolactone in the management of resistant hypertension: a surveillance study. [2007.04]
Treatment of polycystic ovary syndrome with spironolactone plus licorice. [2007.03]
|
